Information about Lipaspan
LIPASPAN ER Tablets for oral administration contain: 500 or 1000 mg of Niacin.
Indications and usage:
Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate, as follows:
1. To patients with primary hyperlipidemia and mixed dyslipidemia.
2. In combination with lipid lowering products as statins derivatives , for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with Niacin or statins monotherapy is considered inadequate.
3. To patients with a history of myocardial infarction and hyperlipidemia. it is indicated to reduce the risk of recurrent nonfatal myocardial infarction.
4. To patients with a history of coronary artery disease (CAD) and hyperlipidemia, it is indicated in combination with a bile acid binding resin, to slow progression or regression of atherosclerotic disease.
5. In combination with a bile acid binding resin, it is indicated to reduce elevated TC and lDl-C levels in adult patients with primary hyperlipidemia (Type IIa).
6. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.
Dosage and administration:
Lipaspan extended-Release should be taken at bedtime, after a low-fat snack, and individualized according to patient response.
Therapy with Lipaspan extended-Release must be initiated at 500 mg at bedtime.
Initiation of therapy:
1 to 4 weeks 500 mg daily at bedtime
5 to 8 weeks 1000 mg daily at bedtime, Thereafter "According to response" 1500 to 2000mg daily at bedtime.
The daily dosage of Lipaspan extended-Release should not be increased by more than 500 mg in any 4-week period and doses above 2000 mg daily are not recommended.
Pack of 28 F.C Tablets for each strength.